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Magnetic resonance imaging in lung: a review of its potential for radiotherapy
Abstract
MRI has superior soft-tissue definition compared with existing imaging modalities in radiation oncology;
this has the added benefit of functional as well as anatomical imaging. This review aimed to evaluate the
current use of MRI for lung cancer and identify the potential of a MRI protocol for lung radiotherapy (RT).
30 relevant studies were identified. Improvements in MRI technology have overcome some of the initial
limitations of utilizing MRI for lung imaging. A number of commercially available and novel sequences
have shown image quality to be adequate for the detection of pulmonary nodules with the potential for
tumour delineation. Quantifying tumour motion is also feasible and may be more representative than that
seen on four-dimensional CT. Functional MRI sequences have shown correlation with flu-deoxy-glucose
positron emission tomography (FDG-PET) in identifying malignant involvement and treatment response.
MRI can also be used as a measure of pulmonary function. While there are some limitations for the
adoption of MRI in RT-planning process for lung cancer, MRI has shown the potential to compete with
both CT and PET for tumour delineation and motion definition, with the added benefit of functional
information. MRI is well placed to become a significant imaging modality in RT for lung cancer.
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REVIEW ARTICLE
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ABSTRACT
MRI has superior soft-tissue definition compared with existing imaging modalities in radiation oncology; this has the
added benefit of functional as well as anatomical imaging. This review aimed to evaluate the current use of MRI for lung
cancer and identify the potential of a MRI protocol for lung radiotherapy (RT). 30 relevant studies were identified.
Improvements in MRI technology have overcome some of the initial limitations of utilizing MRI for lung imaging. A number
of commercially available and novel sequences have shown image quality to be adequate for the detection of pulmonary
nodules with the potential for tumour delineation. Quantifying tumour motion is also feasible and may be more
representative than that seen on four-dimensional CT. Functional MRI sequences have shown correlation with flu-deoxyglucose positron emission tomography (FDG-PET) in identifying malignant involvement and treatment response. MRI can
also be used as a measure of pulmonary function. While there are some limitations for the adoption of MRI in RT-planning
process for lung cancer, MRI has shown the potential to compete with both CT and PET for tumour delineation and
motion definition, with the added benefit of functional information. MRI is well placed to become a significant imaging
modality in RT for lung cancer.

INTRODUCTION
Radiotherapy (RT) plays a signiﬁcant role in the treatment
of lung cancer1 and relies on accurate imaging for precise
treatment delivery. Improvements in imaging and the use
of multimodality imaging have improved tumour delineation for RT planning and treatment of lung cancer.2,3
CT is the standard imaging modality in RT with a relatively
high spatial resolution, but limited speciﬁcity. Tumour
deﬁnition on CT can be obscured in the presence of adjacent lung collapse or consolidation. The incorporation of
positron emission tomography (PET) with glucose analogue ﬂu-deoxy-glucose (FDG) tracer has signiﬁcantly
improved the discrimination between benign and malignant
tissue.4 The use of FDG-PET has reduced gross tumour
volumes (GTV) owing to the improved differentiation between benign and malignant tissue5–7 and reduced interobserver variability in the delineation of GTV.4–13 While
FDG-PET with CT is currently the standard of care for

tumour delineation, there are limitations. The spatial resolution of PET is poor, ranging between 5 and 7 mm compared with 2 mm for CT.14 This low spatial resolution results
in blurred edges, and tumours ,4 mm may be falsely negative on FDG-PET scans. There is also a lack of consensus on
the FDG-PET visualization method within RT, with a number of different methods reported in the literature.6–9,13,15
Use of ionizing radiation to acquire images for PET and CT
can be a limiting factor in repeated examinations.
The mobility of tumour and normal anatomy during
respiration can lead to a large degree of uncertainty in
tumour position. In order to visualize and quantify tumour motion, a number of options have been utilized
including ﬂuoroscopy, slow CT scans and breath-hold
devices.16 However, these have largely been superseded
by respiratory-correlated CT or four-dimensional CT
(4DCT).17 4DCT image acquisition is based on acquiring
CT images with an external respiratory trace while the
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Figure 1. Comparison of 3-T axial T1 weighted breath-hold at inspiration gradient-echo sequence (volumetric interpolated breathhold) (a) and T2 weighted turbo spin-echo navigator sequence (half-Fourier acquisition single-shot turbo spin echo) at the exhale
phase (b). The image in (b) demonstrates tumour infiltration into the mediastinum abutting the superior aspect of the aortic arch.

patient is free breathing. During post processing, the acquired
images are correlated with an external respiratory signal
usually either in the form of a reﬂective marker and camera
system or a pressure-sensing belt around the abdomen. The
advent of 4DCT in RT planning has overcome some of the
problems associated with imaging the thorax18 and has
allowed for the deﬁnition of patient-speciﬁc margins for tumour motion.19–21 However, accurate deﬁnition of motion on
4DCT is reliant on a consistent respiratory cycle.22
MRI is a well-established diagnostic tool in oncology.23 Unlike
CT where tissue contrast primarily depends on electron density,
MRI contrast can be varied extensively by imaging other intrinsic properties of the tissue (e.g. spin lattice and spin–spin
relaxation time, proton density, diffusion etc.). Typically, a MRI
examination will consist of multiple series of scans in several
imaging planes using different pulse sequences which exploit
these properties.24 This allows ﬂexibility in facilitating optimal
tumour visualization and evaluation.23 The beneﬁt of MRI in
delineating soft tissues has been demonstrated for a number of
disease sites in RT23,25,26 and is being incorporated into the
treatment-delivery process with the development of MRI linear
accelerators,27–29 making it a signiﬁcant imaging modality in
future. The use of MRI in the lung has been complicated by
ﬁrstly by respiratory motion and also low proton density of the
lung tissue, which can reduce the signal-to-noise ratio and increase magnetic susceptibility effects.30
Improvements in technology (most notably parallel imaging)
resulting in faster acquisition times and better respiratory-gating
techniques (e.g. navigator echoes) have signiﬁcantly improved
the quality of lung MRI.31,32 Development of any MRI protocol
for the lung needs minimization of the impact of susceptibility
and motion artefacts on the image quality. A lung protocol for
diagnostic imaging has been described31,33 and it consists of
a combination of T2 and T1 weighted images (Figure 1). T2
weighted images highlight tumour inﬁltration and nodular
lesions or masses with high ﬂuid content, and T1 weighted
images cover high-signal pulmonary nodules and masses. For
the detection of mediastinal lymph nodes, a T2 weighted scan
with fat saturation is recommended. A healthy lung generally has
low signal intensity on MRI, and the presence of nodules or
masses with increased proton density improves signal and
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contrast with the surrounding lung and therefore potential
detection.33,34
OBJECTIVE
The aim of this study was to review the current status and
developments in lung MRI in order to evaluate its potential role
in: (i) target volume delineation, (ii) tumour motion quantiﬁcation (iii) and functional imaging for lung cancer RT and to
identify the sequences necessary to achieve these.
METHODS AND MATERIALS
A literature search was performed using PubMed, Medline and
Google Scholar using the terms listed in Table 1 for articles
published between 1990 and September 2014. The keyword
combinations, A–H, listed in Table 1 were entered into the
search strategies for each of the databases deﬁned above to
identify appropriate literature. The literature review was limited
to articles written in English and on human subjects. The results
were grouped according to three major areas: (1) MRI-based
anatomical imaging with the potential for tumour delineation,
(2) MRI-based tumour motion analysis and (3) MRI-based
functional imaging.
RESULTS
30 publications were identiﬁed which met the selection criteria,
3 publications on the anatomical detection of tumour (Table 2),
9 publications on motion analysis using MRI (Table 3) and 18
Table 1. Search keywords

Keywords

Keyword combinations

(1) Lung
(2) Cancer
(3) Thorax
(4) Thoracic
(5) Radiotherapy
(6) Radiation therapy
(7) MRI
(8) MRI
(9) MR
(10) Anatomical
(11) Motion
(12) Functional

A: (1 and 2), (5 or 6) and (7 or 8 or 9)
B: (1 and 2) and (7 or 8 or 9)
C: (3 or 4) and (5 or 6) and (7 or 8 or 9)
D: (3 or 4) and (7 or 8 or 9)
E: (A) and (10 or 11 or 12)
F: (B) and (10 or 11 or 12)
G: (C) and (10 or 11 or 12)
H: (D) and (10 or 11 or 12)
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Table 2. Literature summary of scan protocols for studies evaluating MRI-based anatomical detection of lung cancer

Reference
Biederer
et al35

Scanner
1.5T
(Siemens)

Bruegel
et al36

Acquisition
plane

Protocol
3D GRE VIBE
T2 HASTE,
T2 IR-HASTE,
T2 TSE,
STIR,
VIBE

1.5T
(Siemens)

Coronal

Breath-hold 20 s

Vessels and airways

Axial

Breath-hold 14–19 s at end
inspiration

Pulmonary lesions

STIR
Chin et al37

Respiratory and pulse triggered

T2 triple-inversion
black-blood TSE,
T1 3D TSE

3T (Phillips)

Physiology
assessed

Breathing manoeuvre

Axial

Breath-hold 16 s

Pulmonary nodules

3D, three-dimensional; GRE, gradient-recalled echo sequence; HASTE, half-Fourier acquisition single-shot turbo spin echo; IR-HASTE, inversion
recovery HASTE; STIR, short-tau inversion recovery; TSE, turbo spin echo; VIBE, volumetric interpolated breath-hold.
GE; Milwaukee, WI; Phillips, Amsterdam, Netherlands; Siemens, Erlangen, Germany.

publications on functional MRI for lung tumour and pulmonary
nodules including functional imaging of healthy lung (Table 4).
The majority of the studies were conducted on 1.5-T scanners
using a combination of breath-hold and free-breathing scans
with and without respiratory and/or cardiac gating. Most protocols used fast-imaging-sequence variants of both the gradientecho (GRE) or turbo-spin echo techniques. In most cases,

parallel imaging—using radiofrequency coil encoding—was
applied to further reduce the scan time and limit the breath-hold
duration required. Table 5 highlights the basic sequences used
and their applications and limitations in lung imaging. While
there was evidence available for lung cancer imaging from a diagnostic perspective, there was limited evidence in its application in radiation oncology imaging.

Table 3. Literature summary of studies evaluating MRI-based tumour motion

Reference

Scanner

Protocol

Acquisition plane

Biederer
et al38

1.5T
(Siemens)

3D GRE

Coronal

Phantom study

Porcine heart and lung
collocated into a chest
phantom

Cai et al39

1.5T
(Siemens)

TrueFISP

Sagittal

Quiet breathing

Tumour and lung motion

Cai et al40

1.5T
(Siemens)

TrueFISP

Sagittal

Normal breathing cycle—
300-s continuous scan

Tumour and healthy lung

Koch et al41

1.5T (GE)

FSE
fGRE

Sagittal coronal and axial

NA

Phantom

Liu et al42

1.5T (GE)

fGRE—
modiﬁed

Axial, sagittal and coronal

Free breathing

Pulmonary vessels

Plathow
et al43

1.5T
(Siemens)

TrueFISP

Lung motion—coronal;
tumour motion—sagittal,
coronal

Quiet tidal breathing followed
by maximum inspiration and
expiration

Tumour volume,
lung volume

Plathow
et al44

1.5T
(Siemens)

TrueFISP

Lung motion—coronal;
tumour motion—sagittal,
coronal and axial

Quiet tidal breathing followed
by maximum inspiration and
expiration

Lung and tumour volume

Blackall
et al45

1.5T
(Phillips)

Coronal

Breath-hold 15 s at tidal
inhalation and exhalation

SSFP
FFE

Koch et al46

1.5T (GE)

fGRE—
modiﬁed

Breathing manoeuvre

Physiology assessed

Lung and tumour motion

Free breathing
Axial,
sagittal and coronal

Free breathing

Pulmonary vessels

3D, three-dimensional; FFE, fast field echo; fGRE, fast gradient echo; FSE, fast spin echo; GRE, gradient echo; NA, not applicable; SSFP, steady-state
free precession; TrueFISP, true fast imaging with steady-state precession.
GE; Milwaukee, WI; Phillips, Amsterdam, Netherlands; Siemens, Erlangen, Germany.
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0, 5, 10, 15, 20,
25, 50,
80, 150, 300,
500, 800
NA

500

DWI (EPI
with SE)

IVIM—DWI (EPI
with SS)
respiratory gated

T1 3D VIBE

DWI (EPI with
SS SE 1 ASSET)

1.5T
(Siemens)

1.5T
(Phillips)

1.5T
(Siemens)

Abdel
Razek
et al50

Xu et al51

Wang
et al52

1.5T (GE)

NA

0, 1000

DWI (EPI
with SE)

1.5 T
(Siemens)

Pauls
et al49

Yang
et al53

ADCmean

0, 400, 800

DWI (EPI
with SS)

NA

NA

T2 FRFSE
respiratory
and cardiac gated

0, 300, 600

NA

T1 SE; respiratory
and
cardiac gated

DCE (T1 2D
GE1FLASH)

1000

DWI (EPI
with SE)

1.5T
(Phillips)

NA

NA

ADCmean

NA

ADCmean

NA

NA

ADCmin

NS

Mori
et al48

0, 400, 1000

1.5T
(Siemens)

ADC
parameter

Lichy
et al47

b-value
(s mm22 )

DWI (EPI with
SE),
respiratory gated

MRI protocol

Scanner

Author

Table 4. MRI-based functional imaging

Transverse

Transverse

Transverse

Transverse

Transverse

Transverse

Transverse

Transverse

Transverse

Transverse

Transverse

Acquisition
plane

Free breathing

Free breathing

Breath-hold

Breath-hold

Free breathing

Free breathing

NS

NS

NS

Shallow breathing

Free breathing

Breathing
manoeuvre

FDG-PET

FDG-PET histology

Histology

Histology

FDG-PET (uptake—NS)

FDG-PET
(SUVmax, SUV-CR)

(Continued)

DWI images were equivalent to
PET in the differentiation
between tumour and atelectasis;
T2 images allowed
differentiation between tumour
and atelectasis then T1; SCLC
had higher ADC values than
SCC and AC

IVIM parameters were lower
and DCE parameters were
higher in the presence of
disease when compared with
consolidation; however, there
was poor correlation between
IVIM and DCE parameters

Visual detection of malignant
nodes was higher than that of
benign nodes; subsequently,
ADC values were signiﬁcantly
lower for malignant nodes
when compared with
benign nodes

Mean ADC values for
malignant disease signiﬁcantly
lower than benign nodes

T1 DCE images were
equivalent to DWI in nodal
detection when compared
with PET; DCE and DWI
understaged nodal disease
when compared with PET

Inverse correlation between
ADCmin and SUV-CR; DWI
had higher sensitivity in the
presence of inﬂammation

FDG-PET (uptake
value, NS)

Outcome
Metastatic disease DWI at
b51000 s mm22 corresponded
to that on FDG-PET images;
ADC maps did not improve
nodal detection

Image reference

BJR
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1.5T
(Siemens)

1.5T (GE)

Hunter
et al59

Pauls
et al61

3T
(Siemens)

Chen
et al58

1.5T
(Phillips)

DWI (EPI
with SE)

1.5T
(Siemens)

Iizuka
et al57

Regier
et al60

DWI (EPI)
respiratory gated

1.5T
(Phillips)

Yabuuchi
et al56

T1 sGRE
NA

NA

0, 500

EPI with SE;
respiratory
triggered

T1 3D GRE

NA

50, 1000

0, 500, 1000

0, 1000

T1 DCE with EPI
T1 SE

DCE with SE

DWI (EPI)
respiratory
and pulse-gated

600

DWI (EPI
with ASSET)

3T (GE)

Chang
et al55

1, 1000

b-value
(s mm22 )

DWI (EPI
with STIR)

3T (GE)

Ohno
et al54

MRI protocol

Scanner

Author

Table 4. (Continued)

NA

NA

ADCmin and
ADCmean

Transverse

Transverse

Transverse

Transverse

ADCmean,
ADCmedian
and ADCmin

NA

Transverse

Transverse

Transverse

Transverse

Acquisition
plane

ADCmedian

ADCmean

ADCmean

ADCmean

ADC
parameter

Maximum end
inspiration
breath-hold

Breath-hold
(,20 s)

Free breathing

Quiet breathing

Free breathing

Free breathing

Breath-hold

Free breathing

Breath-hold

Free breathing

Breathing
manoeuvre

Histology

FDG-PET (SUVmax and
SUVmean)

FDG-PET (MRGIc)

Histology

FDG-PET (SUVmax)

NA

NA

FDG-PET (SUVmax)

Image reference

(Continued)

DCE parameters allowed
differentiation between
tumour subtypes

Inverse correlation between
ADCmin and SUVmax

Tumour vascular physiology
as measured on DCE
correlated with glucose
metabolism; changes in
vascular physiology noted
during and after treatment

Signiﬁcant inverse
relationship between tumour
cellularity and ADC mean and
minimum values

No correlation noted between
SUVmax and ADCmedian;
however, patients with low
ADC value and high SUVmax
demonstrated disease
progression

Correlation between early
ADC change and
post-treatment tumour size;
better progression-free
survival in patients with
increased ADC

Patients who responded to
treatment demonstrated
increased ADC values; those
who had no treatment response
had a slight decrease in ADC

DWI (ADC) may have better
potential than FDG-PET
(SUVmax) for the prediction of
tumour response during
chemoradiotherapy for NSCLC

Outcome

Review article: MRI in lung radiotherapy
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1.5T
(Philips)
Shiabata
et al64
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2D, two-dimensional; 3D, three-dimensional; AC, adenocarcinoma; ADC, apparent diffusion coefficient; ADCmean, mean apparent diffusion coefficient; ADCmedian, median apparent diffusion
coefficient; ADCmin, minimum apparent diffusion coefficient; ASSET, array spatial sensitivity encoding technique; bFFE, balanced fast-field echo; DCE, dynamic contrast-enhanced; DWI,
diffusion-weighted imaging; EPI, echoplanar imaging; FLASH, fast low-angle shot; FDG, fludeoxyglucose; FRFSE, fast-recovery fast spin echo; GE, gradient echo; GRE, gradient echo; IVIM, intravoxel
incoherent motion; MRGIc, glucose metabolic rate; NA, not applicable; NS, not specified; NSCLC, non-small-cell lung cancer; PET, positron emission tomography; SCC, squamous cell carcinoma;
SCLC, small-cell lung cancer; SE, spin echo; sGRE, spoiled gradient echo; SS, single shot; STIR, short-tau inversion recovery; SUV, standardized uptake value; SUV-CR, contrast ratio for standardized
uptake value; SUVmax, maximum standardized uptake value; SUVmean, mean maximum standardized uptake value; TrueFISP, true fast imaging with steady-state free precision; VIBE, volumetric
interpolated breath-hold.
GE, Milwaukee, WI; Phillips, Amsterdam, Netherlands; Siemens, Erlangen, Germany.

Correlation between
spirometry and
respiratory motion
Forced deep
breathing
NA

1.5T
(Siemens)
Plathow
et al63

bFFE

NA

Mid-sagittal
plane

Spirometry

MRI dimensions and
spirometry data demonstrated
signiﬁcant correlation
Spirometry
NA
NA

Free breathing
followed by
maximum
inspiration and
expiration
Coronal,
sagittal
and transverse
TrueFISP

Breath-hold
Not speciﬁed
1.5T (GE)
Iwasawa
et al62

NA
NA
DCE with SE

Scanner
Author

Table 4. (Continued)

MRI protocol

b-value
(s mm22 )

ADC
parameter

Acquisition
plane

Breathing
manoeuvre

Image reference

DCE MRI with perfusion data
allows evaluation of
pulmonary perfusion

Kumar et al

Outcome

BJR

MRI-based anatomical imaging with the potential for
tumour delineation
No studies speciﬁcally looked at lung tumour delineation based on
MRI; however, three articles investigated the utility of MRI in detecting pulmonary nodules.35–37 A T1 weighted three-dimensional
(3D) spoiled GRE sequence with volumetric interpolated breathhold (VIBE) demonstrated a pulmonary nodule-detection rate
comparable with CT. However, with participants who were not
compliant with the breath-hold manoeuvre, blurring and ghosting
artefacts impacted image quality.35 Two studies evaluated breathhold T1 and T2 weighted turbo spin-echo sequences to detect
pulmonary nodules in the axial plane.36,37 MRI was able to
detect nodules between 5 and 10 mm.37
The main challenges for imaging in the lung are susceptibility
and motion artefacts. The sequences described for pulmonary
nodule detection have different applications and limitations in
lung imaging. VIBE35,36 is a 3D fast T1 weighted spoiled GRE
sequence, which is particularly robust in the presence of cardiac
pulsation. With its high spatial resolution, it allows the detection
of relatively small pulmonary nodules in 3D. The inherent speed
of this sequence means it can be acquired in a single breathhold.65 It is therefore ideal in pulmonary imaging, where the
entire thorax can be acquired in one breath-hold. It is, however,
very sensitive to respiratory motion, which can result in signiﬁcant motion-related artefacts. Being a GRE sequence, it is
also prone to susceptibility artefacts especially at 3 T. T2
weighted sequences suffer from longer acquisition times
(Table 5) and therefore require gating or multiple breath-holds
to be employed. To help further reduce the scan time of fast spin
echoes, half-Fourier acquisition single-shot turbo spin echo has
been used.36 These sequences combine the speed-up advantages
of acquiring half of the k-space data together with a single
repetition time (TR) or “shot”.65. However, this makes it prone
to blurring, which may be an issue when deﬁning the tumour
volume for RT. Inversion-recovery (IR) sequences36 with black
blood contrast have also been investigated. IR protocols allow
robust differentiation between the fat and water owing to the
added inversion time to null the signal from the fat rather than
using radiofrequency-suppression pulses. This makes it ideal for
identifying the tumour and nodal volume close to the mediastinum as subcutaneous fat and bone marrow of the ribs will be
saturated, allowing for greater visibility of the area of oedema
and inﬂammation. However, it has “longer acquisition times
caused by longer TRs, low signal-to-noise and tissues with
similar T1 values will all be suppressed”.66
Miller et al32 also highlighted the use of ultrashort echo-time
(UTE) sequences to improve structural imaging. The development
of UTE offers two speciﬁc advantages in lung imaging; acquiring
signal at tens of microseconds minimizes susceptibility artefacts
and allows image acquisition at extremely short relaxation times in
lung. The resultant image provides similar contrast to that of CT.
To date, this sequence has not been studied for the deﬁnition of
tumour or pulmonary nodules.
MRI-based tumour motion
To capture respiratory motion during free breathing, real-time
imaging is required. The majority of the studies assessing

Br J Radiol;89:20150431
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Table 5. MRI sequence adaption for lung imaging

Sequence
description

Type

T2 weighted anatomy

Fast spin echo with gating (e.g. TSE/
FSE or HASTE)

Long scan time requires gating or
multiple breath-holds

Self-navigation using amplitude
or phase

T1 weighted anatomy

3D volume gradient echo (e.g. VIBE,
LAVA) without gating

Breath-hold duration

Parallel imaging, partial k-space to
reduce time of scan

Real-time motion

Steady state (e.g. TrueFISP,
bSSFP, FIESTA)

Off-resonance and cardiac artefacts

Select appropriate FOV and use
speciﬁc cardiac shim

Diffusion

Echoplanar imaging

EPI artefacts; low spatial resolution

Shaped excitation to reduce volume of
the tissue

Perfusion

Dynamic fast gradient echo (e.g.
FLASH, FSPGR) with contrast

Has to be run in one or multiple
breath-holds depending on
requirements

Radial k-space to reduce motion
artefacts with/without motion
correction

Challenges for lung

Further improvements

3D, three-dimensional; EPI, echoplanar imaging; FIESTA, fast imaging employing steady-state acquisition; FLASH, fast low-angle shot; FSE, fast spin
echo; FSPGR, fast spoiled gradient recall echo; FOV, field of view; HASTE, half-Fourier acquisition single-shot turbo spin echo; LAVA, liver acquisition
with volume acceleration; TrueFISP, true fast imaging with steady-state precession; TSE, turbo spin echo; VIBE, volumetric interpolated breath-hold.

tumour motion utilized a variation of GRE sequences.38–44
While there is evidence to suggest that MRI data are prone to
geometric distortion in the presence of motion,30 two studies
demonstrated results contrary to this.41,45 Imaging in the sagittal
and coronal planes demonstrated minimal error when compared
with the axial plane using a thoracic phantom and a fast
gradient-echo (fGRE) sequence.41 The integrity of the structures
was maintained on free-breathing real-time MRI scans, while
a large error was noted for intracycle tidal volume reproducibility on breath-hold scans.45
fGRE sequences were shown to be feasible in assessing lung
motion; however, pulmonary vessels rather than lung tumour
were used for assessment.42,46 Respiratory mechanics of the lung
and tumour can also be assessed with a true fast imaging with
steady-state precession (TrueFISP) sequence.43,44 Plathow et al44
demonstrated a variation in motion between tumour- and nontumour-bearing hemithorax with the motion magnitude varying
according to the tumour location. Variation in the tumour

motion before and after RT was also assessed and showed no
change, although there was a reduction in the craniocaudal
motion of the tumour-bearing hemithorax.43 The change in the
craniocaudal motion of the tumour-bearing hemithorax was not
reﬂected in spirometry results.
Two studies compared the motion measured on real-time
MRI with that seen on 4DCT with conﬂicting results.38,39 In
a phantom study using GRE sequences, Bieder et al38 showed
that the lesion diameter was larger but the lesion displacement smaller on MRI than that on 4DCT. Cai et al39 investigated the internal target volume error between real-time
MRI and simulated 4DCT data. The results indicated that
owing to the nature of 4DCT acquisition, the excursion of
tumour motion may not be accurately depicted on a 4DCT
scan. The magnitude of internal target volume error correlated with the variability in participants’ breathing. Acquiring
tumour motion data over a prolonged period was shown to be
more accurate than limited breathing cycles.40

Figure 2. 3-T coronal true fast imaging with steady-state precession (TrueFISP) images without (a) and with (b) dedicated cardiac
shim to minimize off-resonance artefacts.
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Steady-state-free precession sequences are ultrafast GREs
designed around very short TRs and have demonstrated the
required temporal and spatial resolution to acquire multiple
images during free breathing to allow quantiﬁcation of tumour motion.65 These sequences are highly dependent on
ﬁeld homogeneity; it is therefore essential to perform
shimming of the heart prior to acquisition to help minimize
off-resonance artefacts.65 Figure 2 demonstrates a TrueFISP
sequence with and without the cardiac shim, which helps
minimize artefacts. Trade-offs in temporal resolution between two-dimensional (100 ms) and 3D imaging (1 s) can
lead to blurring, unless a slow-breathing manoeuvre is
performed. 67
For tumour motion assessment, an imaging protocol with ultrafast GRE sequences and parallel imaging is appropriate
(Table 5). These usually consist of steady-state sequences (such
as TrueFISP, steady-state free precession etc.) for optimum
temporal resolution.
MRI-based functional imaging
Currently, functional imaging in lung RT satisﬁes two purposes,
identiﬁcation of nodal disease and differentiation between the
tumour and surrounding consolidation. This, in most cases, is
achieved with FDG-PET imaging. The most commonly employed
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functional MRI techniques are diffusion-weighted imaging (DWI)
and dynamic contrast-enhanced (DCE) imaging. Studies looking
at functional imaging included both the tumour and healthy
lung tissue.
DWI is based on sensitizing the sequence to the motion of water
molecules at a microscopic level (described by the b-value of the
image). This motion may be quantiﬁed by generating parametric
maps using at least two different b-value images and calculating
the apparent diffusion coefﬁcient (ADC). Qualitative interpretation of DWI is based on the visual assessment of signal
intensity on a high b-value image set; a region of high signal
intensity depicts restricted diffusion in the extracellular space.
Areas of restricted diffusion will translate to areas of low values
on the resulting ADC map.
A number of studies utilized DWI to assess the presence of
malignant lymph nodes47–51 and detection of tumour in the
presence of consolidation.52,53 Most studies compared DWI with
FDG-PET imaging. DWI was not able to improve the detection
of metastatic mediastinal nodal disease for lung cancer compared with PET;47,48 however, it had higher speciﬁcity in the
presence of inﬂammation.48 Pauls et al49 showed that DWI had
80% agreement with PET for nodal stage with 15% of the cases
understaged and 5% of the cases overstaged. In those cases

Figure 3. Axial diffusion-weighted imaging (echoplanar imaging with ZOOMit) with b-value 0 (a), 250 (b), 500 (c) and 750 (d) of
a 69-year-old male patient with lung cancer diagnosed with large-cell carcinoma of the left upper lobe. There is a marked area of
hyperintensity in the left upper lobe characteristic of restricted diffusion. Artefacts are present, but the image quality is sufficient for
tumour edge definition (d) and apparent diffusion coefficient measurement (e).
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where MRI overstaged the nodal disease, restricted diffusion was
noted in both mediastinal and supraclavicular lymph nodes
(4–7 mm), with no evidence of elevated glucose metabolism.
Nodal disease was adjacent to the primary tumour volume, in
cases where MRI understaged the disease.49 It should be noted
that neither study had pathological correlation of the imaging
results; both were only assessing the agreement between the two
imaging modalities.48,49 Therefore, there is potential for PET to
be false negative in the case of small tumours.
DWI can also differentiate between malignant and benign mediastinal lymph nodes.50 Malignant node detection on preoperative DWI was compared with histologically conﬁrmed
malignant lymph node status post operatively.51 A whole-body
version of DWI termed DWIBS (diffusion-weighted imaging
with background signal suppression) has been used to produce
images that are visually similar to FDG-PET,51 and the visual
detection of malignant nodes on the resultant images was signiﬁcantly higher for both enlarged and normal-size lymph
nodes. ADC values also correlated with the visual detection rate.51
Two studies demonstrated the potential of DWI to differentiate
lung cancer from consolidation. Yang et al53 compared DWI
with FDG-PET. DWI was able to detect the difference between
tumour and consolidation in all patient cases, based on the
hyperintensity of the tumour. The ADC map also demonstrated
lower values in the presence of the tumour. An intravoxel incoherent motion (IVIM) sequence was also able to differentiate
between tumour and consolidation as compared with both DCE
and FDG-PET.52 IVIM is a modiﬁed DWI technique in which
images are acquired with lower than conventional b-values that
are sensitive to blood microcirculation. Both DCE and IVIM
were able to distinguish between cancer and consolidation;
however, there was a poor correlation between IVIM and DCE
parameters.
There is potential for the ADC map to detect early treatmentrelated changes better than FDG-PET.54,55 Increase in the ADC
value in the early phase of treatment correlated with ﬁnal tumour size reduction, indicating potential use in detecting early
treatment response.56 Median progression-free survival in
patients with increased ADC change was shown to be
12.0 months compared with 6.7 months for those patients where
ADC remained stable or decreased.56 To predict disease progression following stereotactic RT for stage I non-small-cell lung
cancer, Iizuka et al57 performed pre-treatment DWI and FDGPET. Patients with low ADC value and higher SUVmax had
greater disease progression, but results were not statistically
signiﬁcant. From a slightly different perspective, Chen et al58
demonstrated an inverse relationship between minimum and
mean ADC values and tumour cellularity.
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with EPI to eliminate motion artefact using only a single
b-value, it is more common practice to acquire two or more
b-values for the quantiﬁcation of tumour diffusion. There is
potential to improve EPI for lung DWI (Table 5) in the lung, by
reducing the volume of the excited tissue and limiting artefacts
from tissue outside this ﬁeld of view. Figure 3 illustrates an
example of DWI using EPI combined with reduced excitation.
DCE involves the acquisition of images before, during and after
administration of a suitable contrast agent. Data may be evaluated and quantiﬁed in a number of ways, from simple measurements to complex pharmacokinetic modelling.69 Highly
perfused regions demonstrate a high and rapid uptake and
washout of gadolinium-based contrast. DCE for perfusion assessment of lung cancer requires high temporal resolution in
order to adequately assess the enhancement of the tumour
volume. fGRE sequences are generally utilized with partial or
shared k-space approaches to optimize temporal resolution and
run with multiple short breath-hold manoeuvres over the required time course. It has recently become feasible to acquire
this data during free breathing by using a radial stack of stars
(Table 5), sampling scheme to compensate or even correct for
motion.70 Free-breathing perfusion data have been shown to be
as reproducible as breath-hold and also better tolerated. However, further investigation is required for adaption in lung
imaging.71
Two studies highlighted a possible relationship between metabolic activity and cellularity.59,60 Tumour vascularity59 on DCE
and restricted diffusion60 as measured on ADC were found to be
correlated to increased FDG uptake or SUVmax on PET scans.
Hunter et al59 also demonstrated changes in vascular physiology
which were apparent during and after treatment, highlighting
the potential role in clinical management. DCE perfusion
parameters can also allow identiﬁcation of histological subtypes
for lung cancer.61 A number of contrast-uptake parameters were
used to investigate correlation with tumour subtypes, and these
played a signiﬁcant role in differentiating non-small-cell lung
cancer (NSCLC) from small-cell lung cancer (SCLC). Timedependent kinetic parameters were more relevant in differentiating adenocarcinoma from squamous-cell carcinoma.
Functional MRI data can also be used to assess healthy lung
function prior to the course of treatment. Iwasawa et al62 evaluated whether functional MRI could predict post-operative lung
function. A correlation was seen between the perfusion ratio on
MRI and radionuclide study (scintigraphy) and also between the

Table 6. Image modality comparison table

Imaging modality

Radiotherapy end point
The main application of DWI has primarily been in imaging
neurological disorders. However, there is increasing evidence to
utilize it in imaging for cancer detection and treatment monitoring.68 Echoplanar imaging (EPI) sequences are commonly
used for DWI but are prone to susceptibility distortion and
ghosting artefacts.65 While a breath-hold scan can be performed
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CT

PET

MRI

Tumour volume delineation

U

3

U35–37

Tumour motion assessment

U16–21

3

U38–46

Functional information

3

U4

U47–63

PET, positron emission tomography.
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predicted FEV1 on MRI and the tested FEV1 post operatively.
MRI can also be a useful tool in evaluating respiratory mechanics and volumetry. Using the diaphragm and chest wall
motion as measured on MRI imaging, Plathow et al63 created
a volumetric model to calculate vital capacity and compared this
with spirometry-based vital capacity measurement as lung
function tests. They were able to show a strong correlation between the vital capacity measurement on MRI and that measured on spirometry. Similarly, Shibata et al64 investigated the
difference in respiratory motion between healthy individuals and
patients with chronic obstructive pulmonary disease, tracking
pulmonary vessels using an in-house developed algorithm. MRIbased respiratory motion correlated strongly with spirometry data.
While not yet in routine clinical use, MRI using hyperpolarized
gases or oxygen enhancement can allow for ventilation studies of
the lung.34 For hyperpolarized imaging, two noble gases are
predominantly used, 3-helium (3He) and 129-xenon (129Xe).
3
He has been used to asses ventilation in post-treatment
assessment72,73 or identifying well-ventilated lung for avoidance of functional lung at the time of treatment planning.74,75
129
Xe has the added advantage in that it can be imaged following
ventilation perfusion and it has been shown to highlight gas
exchange impairment.76 Oxygen-enhanced MRI utilizes pure
oxygen as the contrast agent to study ventilation abnormalities.77
DISCUSSION
Improvements in MRI technology continue to enable the imaging of low-proton-density lung tissue in the presence of respiratory and cardiac motion. The main challenges of lung RT
are accurate identiﬁcation of the GTV and nodal volume, particularly in the presence of pathological changes in the surrounding lung tissue. Accurate measurement of tumour motion
is also necessary to ensure that the RT ﬁeld encompasses appropriate margins. MRI has the potential to help overcome both
these challenges. Table 6 highlights the potential application of
MRI in the RT process of lung cancer.
However, the universal application of MRI in lung RT is currently limited by the ability to generate treatment plans on MRI
data sets and create reference images for treatment veriﬁcation.
Currently, MRI is used for speciﬁc lung cancer cases (e.g. Pancoast tumours) to aid in anatomical delineation; however, the
CT data set is still used for treatment planning. The image
registration process between CT and MRI is prone to error
owing to changes in the position and shape of the organ and
tumour, even if the scans are contemporaneous. A MRI-only RT
workﬂow is being considered for many RT sites and will be
necessary for MRI-guided RT systems such as the MRI linear
accelerator. RT treatment-planning systems still require CT or
CT-equivalent data for dose calculation. A number of methods
have been proposed to derive CT equivalent data from MR
images.78 Assigning bulk density to the entire patient anatomy is
the simplest solution, and has been shown to give acceptable
dosimetric accuracy.79 The previously mentioned UTE sequences may also have a role in improving bone and tissue classiﬁcation and direct CT conversion approaches, which makes their
application in the lung even more interesting.79
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In addition, for lung GTV delineation, detection of a pulmonary
nodule or mass is just as important as being able to deﬁne the
boundary of the nodule or mass. To allow volume deﬁnition,
tumour inﬁltration into the chest wall and or mediastinum is
required along with detection of involved mediastinal lymph
nodes. A combination of sequences is required to facilitate GTV
delineation. T2 weighted images such as half-Fourier acquisition
single-shot turbo spin echo (HASTE) or short-tau inversion
recovery (STIR) can demonstrate tumour inﬁltration. T1
weighted images are ideal for identifying mediastinal lymph
nodes. A limitation of these sequences for anatomical detection
is that they are either breath-hold or respiratory-gated images.
The exhale phase in respiratory gating with bellows or navigation is generally used, as this is the longest period of relaxation
during the respiratory cycle. Knowledge regarding the deformation of tumour volume during the respiratory cycle is
important. Hence, a more dynamic approach to imaging is required or at the very least anatomical scans at inspiration and
expiration to capture the position and shape of the tumour at
the extremes of the respiratory cycle. Imaging requirements for
RT are different from those of diagnostic imaging. Imaging for
RT serves the purpose of tumour and associated nodal volume
delineation rather than detection and staging via diagnostic
imaging. As such, these anatomical image sequences need to be
further assessed in a radiation oncology setting.
There is evidence supporting the value of MRI in quantifying
lung tumour motion. However, the data reported are predominantly based on sagittal and coronal planes, imaging planes
that in most cases are not compatible with the majority of RTplanning systems. Furthermore, image acquisition is generally in
two dimensions with either a single plane or the given number
of planes through the region of interest. This can potentially
neglect any out-of-plane tumour motion during respiration and
introduce geometric errors in the planning process. Further
study into 3D registration and incorporation of non-axial data
into treatment-planning systems is needed. While 4DCT remains
the gold standard for lung tumour motion, it is limited by the
number of breathing cycles acquired and any irregularity in
breathing. Real-time MRI can be acquired over a greater number
of respiratory cycles to better understand and capture motion
over time and is not inﬂuenced by irregular breathing patterns
as 4DCT currently is.
In terms of functional imaging, FDG-PET remains the gold
standard in deﬁning metabolically active disease, particularly in
mediastinal nodes and in the presence of consolidation. There is
evidence to support DWI with ADC mapping and DCE MRI as
an alternative to FDG-PET for assessing functional tumour activity. However, studies to date have all been from a diagnostic
perspective, where the end points are disease presence or absence. For RT, the deﬁnition of the malignant target volume is
necessary. Further research is needed to determine whether MRI
will be a complementary or competing technology for PET
imaging in the lung. The availability of hybrid PET-MR systems
also offers promise for lung imaging.80
While the use of ADC and DWI imaging has been reported
on extensively for lung cancer, it should be noted that
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reproducibility of quoted ADC parameters such as the minimum, maximum and mean is a consideration. Kivrak et al81
demonstrated this in their study of ADC values across six different MRI scanners with a phantom. However, rather than
looking at ADC values, the analysis of histogram distributions81
shows potential and may be better for comparing data acquired
on different scanners.82 Conversely, DWI is reproducible between scanners and has shown good interobserver and intraobserver agreement for lung cancer for tumour sizes .2 cm.83
The ability to differentiate histological subtypes is potentially
useful for patients in whom biopsy conﬁrmation of lung cancer
is not possible, usually owing to underlying lung disease. Histological subtype is important in determining treatment, and
MRI parameters could have a potential role in this.61
However, improvement in the standard EPI technique is required to overcome some of the current limitations of susceptibility and motion artefacts.
Fundamentally, breath-hold MRI scans are challenging for
patients with lung cancer owing to their already limited respiratory function. Further improvements in image technology
and navigation for gating may make breath-hold scans obsolete
in these patients.
Lung function tests prior to the start of any treatment to some
extent dictate whether a patient is able to receive radical or
palliative RT. This is usually based on spirometry to assess lung
function. However, two studies63,64 highlighted the potential of
MRI to predict lung function in patients, which could be useful
in patients who cannot undergo spirometry. Hyperpolarized gasand oxygen-enhanced MRI can potentially allow for the analysis

of lung microstructure and quantify ventilation and perfusion of
the lung. MRI scans can thus provide an anatomical and functional
representation of pulmonary function, which could potentially be
used in RT planning by avoiding areas of a well-functioning lung
and assessing treatment response. However, both techniques are
currently restricted to research settings with limited clinical use.
MRI shows potential for monitoring of early response during
a course of treatment, information which is currently not utilized in RT. There is evidence in the literature to suggest a link
between early changes as seen on functional MRI and progressionfree survival.56 This information can be used to adapt treatment
to an individual patient’s tumour response.
CONCLUSION
Using a combination of free breathing, breath-hold and gated
scans with parallel imaging techniques, the quality of lung imaging has improved, with minimal artefacts from respiratory and
cardiac motion. There are still challenges in adopting MRI for
RT imaging but nevertheless based on the evidence available in
the literature, a potential lung RT-imaging protocol can include
for GTV delineation a T1 and T2 weighted gradient and spinecho sequence either as breath-hold or respiratory gated. Motion
assessment is feasible; however, the incorporation of the motion
data to RT planning needs further investigation. DWI can prove
to be an ideal non-invasive imaging technique to assess functional information and assist in GTV delineation. A DCE scan
has the potential to provide additional information on the vascular nature of the tumour volume and healthy lung perfusion.
However, imaging sequences need to be further assessed in the
radiation oncology setting to evaluate and further develop
RT-speciﬁc requirements.
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